Drug Discovery Platform

Unsurpassed Proprietary Understanding of the mTORC1 Pathway

Navitor has deep and proprietary insights into the biological pathways that regulate mTORC1, the master regulator of cell growth and metabolism. Our drug discovery platform is largely built upon the leading-edge insights of the Company’s scientific founder, David M. Sabatini, MD, PhD. Through an exclusive license with the Whitehead Institute for Biomedical Research, Navitor has access to fundamental intellectual property and know-how from Dr. Sabatini’s laboratory related to activation of the mTORC1 pathway for drug discovery, including proprietary reagents and assays and targeted screening methods for mTORC1 modulators.

Navitor Sensor Programs ─ Proprietary and Tunable mTORC1 Activators

SESTRIN. Sestrin, a recently discovered cellular sensor protein for the amino acid leucine, is a potent natural activator of mTORC1 activity in select tissues, including the brain.

Our lead clinical-stage candidate, NV-5138, which binds to and modulates sestrin, is being evaluated in a Phase 1b study for treatment-resistant depression. NV-5138 has demonstrated rapid upregulation of key synaptic proteins, synaptic remodeling in the prefrontal cortex and hippocampus, sustained antidepressant behavioral responses and compound-specific spectral power changes, as measured by quantitative electroencephalography (qEEG).  We are also exploring the effects of NV-5138 on cognition, memory and learning. 

SAMTOR and CASTOR.   SAMTOR and CASTOR are two other recently discovered cellular sensor proteins for the amino acids methionine and arginine, which activate mTORC1 activity in select tissues in the body.  Our SAMTOR and CASTOR modulator programs are presently in early drug discovery.

The NΛValog Platform – a Breakthrough in Selective mTORC1 Inhibition

Our NΛValog program leverages a medicinal chemistry breakthrough leading to a new generation of inhibitors with unprecedented selectivity for mTORC1. This is a unique class of the first absolutely selective mTORC1 inhibitors, totally preserving mTORC2 activity. Our NΛValog development program is focused on human diseases clearly linked to increased mTORC1 activity that have not been addressable by the previous generations of (non-selective) mTORC1 inhibitors. We are initially targeting chronic kidney disease and believe that our NΛValog platform has broad potential application for age-related diseases.

Back to Top